Review anchor
Beta-1 adrenergic receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Beta-1 adrenergic receptor
CHEMBL213
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Beta-1 adrenergic receptor as ChEMBL target CHEMBL213, mapped to UniProt P08588. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL213
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P08588
Beta-1 adrenergic receptor
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Beta-1 adrenergic receptor matters
Beta-1 adrenergic receptor is reviewed as Beta-1 adrenergic receptor (UniProt P08588); Beta-1 adrenergic receptor shows approved-linked disease relevance led by hypertension. 5 more disease programs remain visible in the same review block.; 10 linked drugs keep this evidence frame grounded.; the current evidence base includes 74 approved drugs, 4459 compounds, and 662 assays, with lead potency reaching pChEMBL 10.6.
Protein context
Beta-1 adrenergic receptor
Beta-1 adrenergic receptor Sequence length is 477 aa.
Review this target as Beta-1 adrenergic receptor, mapped to UniProt P08588. Sequence length is 477 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P08588
Protein
Disease context
hypertension
Beta-1 adrenergic receptor shows approved-linked disease relevance led by hypertension. 5 more disease programs remain visible in the same review block. 10 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ACEBUTOLOL HYDROCHLORIDE, ATENOLOL, BETAXOLOL HYDROCHLORIDE.
Start review with hypertension because it currently carries approved-linked support. Linked drugs include ACEBUTOLOL HYDROCHLORIDE, ATENOLOL, BETAXOLOL HYDROCHLORIDE, BISOPROLOL FUMARATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
10 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 74 approved drugs, 4459 compounds, and 662 assays for this target. The dominant activity type is IC50. CHEMBL2012522 is the current potency anchor at pChEMBL 10.6.
Use CHEMBL2012522 as the tractability anchor when discussing potency (pChEMBL 10.6).
Activity source · ChEMBL 36 via Core Engine
74 approved
pChEMBL 10.6
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Beta-1 adrenergic receptor matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P08588, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why hypertension is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
4459
Total Compounds
662
Total Assays
74
Approved Drugs
IC50: 1510.0, KI: 1342.0, EC50: 1097.0, KD: 154.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL2012522
|
10.6 | Ki | — |
|
|
No preferred name
CHEMBL2011218
|
10.4 | IC50 | — |
|
|
No preferred name
CHEMBL2011227
|
10.3 | IC50 | — |
|
|
No preferred name
CHEMBL2011226
|
10.3 | IC50 | — |
|
|
No preferred name
CHEMBL5207281
|
10.1 | Kd | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
BREXPIPRAZOLE
CHEMBL2105760
|
2015 |
|
|
CARIPRAZINE HYDROCHLORIDE
CHEMBL2024517
|
2015 |
|
|
OLODATEROL
CHEMBL605846
|
2014 |
|
|
OLODATEROL HYDROCHLORIDE
CHEMBL2105743
|
2014 |
|
|
INDACATEROL
CHEMBL1095777
|
2009 |
|
|
ARFORMOTEROL
CHEMBL1363
|
2006 |
|
|
DARIFENACIN
CHEMBL1346
|
2004 |
|
|
FORMOTEROL
CHEMBL1256786
|
2001 |
|
|
CARVEDILOL
CHEMBL723
|
1995 |
|
|
SALMETEROL
CHEMBL1263
|
1994 |
|
|
SOTALOL
CHEMBL471
|
1992 |
|
|
PROPAFENONE
CHEMBL631
|
1989 |
|
|
CARTEOLOL
CHEMBL839
|
1988 |
|
|
ESMOLOL
CHEMBL768
|
1986 |
|
|
LEVOBUNOLOL
CHEMBL1201237
|
1985 |
|
|
BETAXOLOL HYDROCHLORIDE
CHEMBL1691
|
1985 |
|
|
BETAXOLOL
CHEMBL423
|
1985 |
|
|
ACEBUTOLOL
CHEMBL642
|
1984 |
|
|
LABETALOL
CHEMBL429
|
1984 |
|
|
PINDOLOL
CHEMBL500
|
1982 |
|
|
ALBUTEROL
CHEMBL714
|
1981 |
|
|
ATENOLOL
CHEMBL24
|
1981 |
|
|
TIMOLOL
CHEMBL499
|
1978 |
|
|
METOPROLOL
CHEMBL13
|
1978 |
|
|
PROPRANOLOL
CHEMBL27
|
1967 |
|
|
EPINEPHRINE
CHEMBL679
|
1965 |
|
|
ISOPROTERENOL HYDROCHLORIDE
CHEMBL1711
|
1956 |
|
|
ISOPROTERENOL
CHEMBL434
|
1956 |
|
|
FENOTEROL
CHEMBL32800
|
— |
Source Header